Condition
Refractory Aplastic Anemia
Total Trials
3
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 1 (1)
P 2 (1)
Trial Status
Terminated1
Not Yet Recruiting1
Unknown1
Clinical Trials (3)
Showing 3 of 3 trials
NCT04854889Phase 2TerminatedPrimary
Efficacy and Safety of Low-dose Decitabine in Refractory Aplastic Anemia
NCT07297550Phase 1Not Yet Recruiting
Safety and Efficacy of the JAK1 Inhibitor Combined With Intensive Immunosuppressive Therapy in Severe Aplastic Anemia
NCT05518331Not ApplicableUnknownPrimary
The Safety and Efficacy Study of Avatrombopag Switch in TPO-RA Refractory AA
Showing all 3 trials